Skip to main content

Table 4 Serum lipids, lipoproteins and apolipoproteins in the three groups

From: Lipoprotein lipase activity and mass, apolipoprotein C-II mass and polymorphisms of apolipoproteins E and A5 in subjects with prior acute hypertriglyceridaemic pancreatitis

 

HPND (N = 20)

HTG (N = 30)

HPD (N = 5)

P

TC

6.36 ± 2.53

6.75 ± 1.58

8.66 ± 6.86

NS

TG

2.67 (1.85–5.00)

4.81 (2.57–7.83)

13.32 (7.69–29.77)

0.006*

VLDL-Chol

0.78 ± 0.41

0.91 ± 0.49

0.98 ± 0.59

NS

HDL-Chol

1.01 ± 0.47

0.91 ± 0.39

0.39 ± 0.13

0.01*

LDL-Chol

3.21 ± 1.40

3.39 ± 1.32

1.45 ± 1.27

0.01 *

VLDL-TG

1.27 (1.02–1.81)

1.39 (1.07–2.49)

1.94 (1.45–3.22)

NS

HDL-TG

0.35 (0.28–0.46)

0.32 (0.25–0.46)

0.21 (0.14–0.44)

NS

LDL-TG

0.56 (0.39–0.64)

0.53 (0.43–0.69)

0.59 (0.46–1.00)

NS

Chylo-Chol

2.95 ± 3.34

2.22 ± 1.58

5.90 ± 7.55

NS

Chylo-TG

3.31 (2.52–7.40)

3.48 (2.21–6.60)

8.49 (5.2–23.81)

0.02**

Apo A-I

1.14 ± 0.29

1.11 ± 0.28

0.54 ± 0.17

<0.001 *

Apo B-100

0.98 ± 0.27

0.98 ± 0.25

0.56 ± 0.37

0.007 *

Apo CII

0.11 ± 0.06

0.13 ± 0.07

0.09 ± 0.05

NS

Apo CIII

0.17 ± 0.07

0.20 ± 0.09

0.19 ± 0.05

NS

Apo E

0.07 ± 0.04

0.11 ± 0.06

0.14 ± 0.03

0.005 *

CIII/CII

2 ± 3

1.7 ± 0.7

5 ± 7

NS

LPLactivity

(mU/ml)

82 ± 34

95 ± 41

0.4 ± 0.5

<0.001 *

HL-activity

(mU/ml)

179 ± 95

195 ± 86

107 ± 47

NS

Posth-LPLmass

(ng/ml)

365 ± 164

422 ± 190

58 ± 27

<0.001*

Preh-LPLmass

(ng/ml)

19 ± 10

22 ± 14

17 ± 12

NS

  1. Data are shown as mean ± SD unless Tg shown as median (IQ range). HPD: patient with LPL deficiency. HPND: HP without LPL deficiency. TC: total cholesterol. TG: triglyceride. *: Differences between HPD and the others groups.** Differences between HPD and HTG group.